An observational study in Asthma, sponsored by National Human Genome Research Institute (NHGRI). Completed at 1 site in United States. Open to participants aged 18 Years to 115 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by National Human Genome Research Institute (NHGRI) · Observational
Background:
Some groups of people have a high prevalence of asthma and allergic disease. Also, asthma and allergic disease are often found in several members of the same family. Researchers want to learn more about what factors might cause asthma, both genetic and environmental.
Objective:
To build a collection of information to try to find genes that cause conditions and disorders such as asthma and allergic disease.
Eligibility:
People ages 18 99 of self-identified African, African American, or African Caribbean descent who either have no history of asthma or wheeze or have a physician s diagnosis of asthma
Design:
Participants will be screened with an interview by phone or in person.
Participants will fill out a questionnaire about their general health and exposure to allergens and smoke.
Participants will have a physical exam.
Participants will have blood tests.
Participants will provide a skin cell sample. Up to two samples will be taken from the inside of the nose. A brush will be used to take the samples.
Participants will have a breathing test. They will be asked to blow forcefully 3 or more times into a lung function machine.
Participants may have their blood and skin samples sent to a lab. DNA will be extracted from the samples and tested.
Participants blood and skin samples will be stored. Samples may be used in future research studies.
Asthma is a complex disease where the interplay between genetic factors and environmental exposures controls susceptibility and disease progression. In the U.S., there remains an epidemic of asthma that disproportionately affects underrepresented minorities and creates a major public health burden, especially among children. Asthmatics of African ancestry continue to have more severe asthma and more severe clinical symptoms than their non-African counterparts, but few studies have focused on this vulnerable group. The purpose of this study is to expand our previous study, the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA) to integrate multi-omic resources for asthma research in African Diaspora populations and by recruiting new participants. The protocol described herein refers to the recruitment that will take place at the NIH Clinical Center as part of the expansion of CAAPA (CAAPA2).
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 83 is below the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →National Human Genome Research Institute (NHGRI) is the lead sponsor of 199 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
African American adults with asthma and healthy controls
Individuals age 18 to 99 of self-identified African, African American, or African Caribbean ancestry who either have no history of asthma or wheeze (controls) or have a physician s diagnosis of asthma. This study focuses exclusively on African ancestry individuals in order to address a lack in the field of asthma research focusing on those of African ancestry despite the greater disease burden experienced by these individuals. Enrollment for the CAAPA2 study at the NIH CC will include only adults, while children will be enrolled at other CAAPA2 sites, consistent with expertise at those sites.
EXCLUSION CRITERIA:
persons with asthma
persons without asthma
Expand and integrate multi-omic resources for asthma research in African Diaspora populations and identify novel genetic determinants for risk of asthma in CAAPA cohorts
Expand and integrate multi-omic resources for asthma research in African Diaspora populations and identify novel genetic determinants for risk of asthma in CAAPA cohorts
Time frame: single assessment
Plan to share: Yes — All collected IPD to be shared with CAAPA2 research team. De-identified IPD to be shared with CAAPA2 investigators. De-identified IPD will be shared with appropriate NIH-sponsored databases such as dbGAP and data underlying a publication may be shared with a journal requiring it for publication.
Supporting information: Study protocol
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Human Genome Research Institute (NHGRI)